Case Study – Quick Look up at DCGI approval of Lundbeck’s Brintellix
Posted on15 Oct 2018
TagsBrintellix, CDSCO, codevelopment deal in pharma, comarketing deal in pharma, copromotion deal in pharma, DCGI, Lundbeck, vortioxetine
Comments0
Lundbeck India Private Limited (LIPL) announces the launch of Brintellix (vortioxetine) in India for the treatment of patients suffering from major depressive... Read More
What is difference between co-promotion and co-marketing deal in pharma?
With co-marketing you have the same product, but different brands. With co-promotion, by contrast, there is only 1 brand, but 2 different... Read More